RxDoctor Payments Data

Lashyra Cotton

Vascular & Interventional Radiology · Cleveland, MSNPI 1205404282

Payments from drug & device makers

What this record shows

Abbott accounts for 65.8% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2023 at $2,632 and has fallen 81.1% since, to $498 in 2025.

$6,253in general payments, 2019–2025

Across 128 payments — averaging $48.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$4K
  • Novartis$473
  • Cordis US CORP.$282
  • Merck$204
  • Alnylam Pharmaceuticals Inc.$204
  • Terumo Medical Corporation$151
  • plus $826 from 15 others

What the payments were for

  • Travel & lodging$3,00948%
  • Food & beverage$3,24452%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few vascular & interventional radiology providers in Mississippito place this figure against a meaningful peer group, so we don't.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan31$27,807
XareltoRivaroxaban32$23,346
EliquisApixaban20$17,282
JardianceEmpagliflozin13$11,286
ClopidogrelClopidogrel Bisulfate83$749
Hydralazine Hcl44$404
Cilostazol27$370
Rosuvastatin Calcium20$278
Losartan Potassium29$273
Furosemide55$265
Bumetanide11$231
Metoprolol Succinate31$213
Carvedilol37$213
Ezetimibe12$196
Pravastatin Sodium26$195

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$473$27,80731 claims
Johnson & JohnsonXarelto$60$23,34632 claims
PfizerEliquis$36$17,28220 claims
Boehringer IngelheimJardiance$41$11,28613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few vascular & interventional radiology providers in Mississippion file to place this against a meaningful peer group, so we don't.

Other vascular & interventional radiology in Cleveland

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →